Who are fluticasone propionate nasal spray + loratadine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluticasone-propionate-nasal-spray-loratadine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

fluticasone propionate nasal spray + loratadine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

fluticasone propionate nasal spray + loratadine (fluticasone propionate nasal spray + loratadine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + antihistamine combination. Area: Allergy/Immunology.

marketed Corticosteroid + antihistamine combination Glucocorticoid receptor (fluticasone); H1-histamine receptor (loratadine) Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

fluticasone propionate nasal spray + loratadine (fluticasone propionate nasal spray + loratadine) — MEDA Pharma GmbH & Co. KG. This combination reduces allergic rhinitis symptoms by suppressing nasal inflammation via corticosteroid action and blocking histamine-mediated allergic responses via H1-receptor antagonism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fluticasone propionate nasal spray + loratadine TARGET	fluticasone propionate nasal spray + loratadine	MEDA Pharma GmbH & Co. KG	marketed	Corticosteroid + antihistamine combination	Glucocorticoid receptor (fluticasone); H1-histamine receptor (loratadine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + antihistamine combination class)

MEDA Pharma GmbH & Co. KG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fluticasone propionate nasal spray + loratadine — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-propionate-nasal-spray-loratadine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab